Introduction
============

Macrolide antibiotics were shown to have immunomodulatory and anti-inflammatory, as well as antibacterial effects (Culic et al. [@b13]; Martinez et al. [@b28]; Kanoh and Rubin [@b23]). In vitro azithromycin inhibits the release of the neutrophil chemoattractant interleukin(IL)-8 and of granulocyte-macrophage colony-stimulating factor (GM-CSF) by lipopolysaccharide (LPS)-activated, human primary bronchial epithelial cells (Murphy et al. [@b32]), and in vivo azithromycin has been shown to inhibit LPS-induced mouse pulmonary neutrophilia (Bosnar et al. [@b8]). In potential agreement with these activities, azithromycin significantly decreased the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients (Albert et al. [@b2]) as well as in non-cystic fibrosis bronchiectasis patients (Wong et al. [@b43]), but the molecular mechanism of its pulmonary anti-inflammatory activity has not yet been elucidated.

Airway infiltration by polymorphonuclear leukocytes (PMNs) in response to bacterial and viral infections represents a pivotal feature of lung inflammatory reactions and is both directly and indirectly involved in most lung pathologies (Murugan and Peck [@b33]). Mobilization of PMNs to inflamed lungs is modulated by a complex interplay between cytokines, endothelial cells, and neutrophils. During the acute-phase response to infectious agents in ruminants and humans, inflammatory cytokines such as IL-1*β*, tumor necrosis factor(TNF)-*α* and IL-8, secreted by a variety of immune and nonimmune cell types, induce a strong PMNs infiltration that sometimes fail to control the infection, and may even contribute to the development of lesions in the lung (Malazdrewich et al. [@b27]; Mukaida [@b31]; Murugan and Peck [@b33]).

Since its discovery in 1986 (Sen and Baltimore [@b39]), the role of ubiquitous nuclear factor-*κ*B (NF-*κ*B) transcription factor has been extensively studied in tumorigenesis, immunity, and inflammatory responses, and its dysregulated activation has been associated with malignancies as well as to inflammatory pathological conditions (Bours et al. [@b10]; Salminen et al. [@b38]; Tornatore et al. [@b41]).

In the lungs, several noxious/inflammatory stimuli activate NF-*κ*B, including intact bacteria, Gram-negative bacterial LPS, ozone, and silica delivered directly to the airways, as well as systemic inflammatory insults such as sepsis, hemorrhage, and direct liver injury (Blackwell et al. [@b6], [@b7]). In rodent models of lung inflammation induced by LPS, pretreatment with relatively nonspecific inhibitors of NF-*κ*B activation was found to decrease lung inflammation (Lauzurica et al. [@b25]), and mice deficient in both RelA (the transactivating subunit of NF-*κ*B) and type 1 TNF receptor (TNFR1) showed impaired neutrophil recruitment to the lungs in response to LPS (Alcamo et al. [@b3]).

To dynamically investigate in vivo, the involvement of NF-*κ*B in the inflammatory response, a transgenic mouse model was developed expressing the minimal promoter of NF-*κ*B and the luciferase gene as a reporter, allowing a direct monitoring of NF-*κ*B activation by bioluminescence (Carlsen et al. [@b11]; Everhart et al. [@b18]; Kielland and Carlsen [@b24]). BLI is based on the detection of light emission from cells or tissues (Doyle et al. [@b17]), and requires an expression cassette consisting of the bioluminescence reporter gene (in this case was luciferase) under the control of a selected promoter (in this experimental setting the NF-*κ*B gene promoter) driving the reporter. To induce light production, the substrate luciferin must be provided by intravascular or intraperitoneal injection immediately prior to bioluminescence imaging (BLI) evaluation. BLI has proven to be a very powerful technique, facilitating real-time, molecular level analysis of disease progression. Nevertheless the generation, characterization, and colony management of transgenic mice may be difficult, and typically very expensive. An alternative, relatively inexpensive approach is represented by the use of transient transgenic mice obtained through the infusion of a polyethylenimine (PEI)/DNA complex containing plasmids with specific responsive elements and luciferase as a reporter gene. This technique yields significant transfection in vivo, as was recently shown by imaging pulmonary NF-*κ*B activation in LPS-treated mice (Ansaldi et al. [@b4]).

In this work, we studied the correlation between lung bioluminescence and lung inflammatory cell infiltration in mice transiently transfected with the luciferase (*luc*) gene under the control of an NF-*κ*B responsive element, upon intratracheal challenge with LPS, and we took advantage of this unique model to provide novel, in vivo evidence that the molecular mechanism of action of the anti-inflammatory activity of the macrolide antibiotic azithromycin involves the modulation of NF-*κ*B activation in lung resident cells.

Materials and Methods
=====================

Animals
-------

Female FVB (7--8 week-old) mice were purchased from Harlan Laboratories Italy (S. Pietro al Natisone, Udine, Italy). Animals were maintained under conventional housing conditions. Prior to use, animals were acclimated for at least 5 days to the local vivarium conditions (room temperature: 20--24°C; relative humidity: 40--70%), having free access to standard rat chow and tap water. All animal experiments were carried out in agreement with the revised "Guide for the Care and Use of Laboratory Animals" ([@b19]) and were approved by the Institutional Animal Care and Use Committee at Chiesi Farmaceutici. The study adhered to the ARRIVE guidelines (McGrath et al. [@b30]).

Reagents
--------

LPS (from Escherichia coli 0111:B4, product n.L3012) was from Sigma (St. Louis, MO); azithromycin (Zitromax) was from Pfizer Inc (Latina, Italy); JetPEI was from Polyplus-transfection Inc (Euroclone, Milano, Italy); NF-*κ*B vector (pGL4.32\[luc2P/NF-*κ*B-RE/Hygro\]) was from Promega (Madison, WI); bortezomib (Velcade) was from Millennium Pharmaceuticals (Cambridge, MA).

Vector characteristic and in vivo gene delivery
-----------------------------------------------

The pGL4.32\[luc2P/NF-*κ*B-RE/Hygro\] vector (GenBank/EMBL Accession Number EU581860) contains five copies of an NF-*κ*B responsive element (NF-*κ*B-RE) that drives transcription of the luciferase reporter gene luc2P (Photinus pyralis). Luc2P is a synthetically derived luciferase sequence with humanized codon optimization that is designed for high expression and reduced anomalous transcription.

The luc2P gene contains hPEST, a protein destabilization sequence. The protein encoded by luc2P responds more quickly than the protein encoded by the luc2 gene upon induction. The vector backbone contains a resistance gene to allow selection in *E. coli* and a mammalian selectable marker for hygromycin resistance.

JetPEI (Wu et al. [@b44]; Oh et al. [@b35]) was applied in vivo as a carrier for delivering DNA to lung tissues. The DNA and JetPEI were formulated according to the product manual. Briefly, 40 *μ*g of NF-*κ*B-luc reporter and 7 *μ*L of JetPEI were each diluted into 100 *μ*L 5% glucose. The two solutions were then mixed and incubated for 15 min at room temperature.

The entire mixture (app.ly 200 *μ*L) was injected into the tail vein of mice.

In vivo bioluminescence imaging
-------------------------------

Transfection per se causes a mild lung inflammatory response and NF-*κ*B activation that is detectable by BLI up to 3--4 days after DNA injection and disappears completely after 1 week. Therefore 1 week after DNA delivery, the transient transgenic mice were injected with luciferin i.p. and BLI was recorded to check the baseline activation of the NF-*κ*B pathway. Briefly, following intraperitoneal injection of luciferin (150 mg/kg) mice were lightly anesthetized with isoflurane (2.5%) and images were obtained using an IVIS imaging system (Caliper Life Sciences, Alameda, CA) at 10 and 15 min after luciferin: an average of photons emitted from the chest of the mice was quantified using Living Image® software (Caliper Life Sciences). The following day, mice were intratracheally challenged with LPS (12.5 *μ*g/mouse) and BLI was recorded at 2, 4, 7, and 24 h after LPS instillation, 15 min after i.p. injection of luciferin (150 mg/kg).

Immunofluorescence staining of luciferase, CD31 and cytokeratin 18 (CK18)
-------------------------------------------------------------------------

To identify the type of cell expressing luciferase protein, duoplex immunofluorescence staining was performed with anti-luciferase antibody and either an anti-CD31 (an endothelial cell marker) or anti-CK18 (an epithelial cell marker). Briefly, during necropsy, 4% paraformaldehyde was first injected through the right ventricle/pulmonary artery to inflate the blood vessel within the lung tissue, and subsequently injected through the trachea to inflate the alveoli. Lung samples were then embedded in paraffin and cut into 5-*μ*m sections, deparaffinized, microwaved in Citra Plus (pH 6; BioGenex, Fremont, CA) for antigen retrieval, and blocked with Antibody Diluent (Dako, Carpintiria, CA). Sections were then incubated with anti-luciferase antibody (Novus Biologicals, Littleton, CO) at 1:100 dilution and 4°C overnight, followed by anti-goat secondary antibody conjugated with Alexa Fluor 594 (Invitrogen, Grans Island, NY) for 1 h. Thereafter, sections were incubated with anti-CD31 antibody (Abcam, Cambridge, MA) at 1:100 dilution for 1 h, followed by anti-mouse secondary antibody conjugated with Alexa Fluor 488 for 1 h, and finally by 4′,6-diamidino-2-phenylindole (DAPI) for 5 min for nuclear staining. For Luciferase/CK18 duoplex staining, after deparaffinization, microwaving and blocking, sections were incubated with an anti-CK18 antibody (Abcam) at 1:500 dilution for 1 h, followed by SuperPicture horseradish peroxidase-conjugated anti-mouse secondary antibody (Invitrogen) for 5 min, and tyramide signal amplification conjugated fluorescein (PerkinElmer, Alameda, CA) for 10 min. Thereafter, sections were microwaved again, blocked and then incubated with anti-luciferase antibody at 1:100 overnight, followed by anti-goat secondary antibody conjugated with Alexa Fluor 594 for 1 h, and DAPI for 5 min for nuclear staining. Images were captured with a Vectra-2 Imaging System (PerkinElmer).

Acute pulmonary inflammation: effect of bortezomib and azithromycin
-------------------------------------------------------------------

Intratracheal (i.tr.) challenge with LPS was carried out using 50 *μ*L of LPS solution (250 *μ*g/mL in phosphate buffered solution \[PBS\]) and a 22-gauge intubator, resulting in a final dose of LPS of 12.5 *μ*g/mouse, with the control group receiving 50 *μ*L of saline i.tr.. In a limited number of mice, 4 h after LPS challenge and luciferin administration, lungs were rapidly excised and BLI recorded at 10 and 15 min after luciferin, as described for intact animals.

Bortezomib was administered by injection into the tail vein at different doses (0.5--1 mg/kg, Psallidas et al. [@b36]) 1 h before LPS i.tr. instillation.

Azithromycin (Zitromax solution) was administered p.o. by gavage at different doses (100--600 mg/kg) (Bosnar et al. [@b8]) 4 h before LPS i.tr. instillation.

Bronchoalveolar lavage and cytokine determination
-------------------------------------------------

Twenty-four hours after LPS challenge, animals were weighted, anaesthetized with isoflurane and sacrificed by bleeding from the abdominal aorta for bronchoalveolar lavage fluid (BALF) collection, performed as previously described (Nassini et al. [@b34]). Bronchoalveolar lavage (BAL) fluid supernatants were frozen at −80°C for simultaneous quantitation of multiple cytokines/chemokines using a Bio-Plex™ Cytokine Assay Kit (Bio-Rad Laboratories, Segrate, Milano, Italy).

The cell pellet was resuspended in 0.2 mL of PBS and cell counts were obtained using a particle counter (Dasit XT 1800J, Cornaredo, Milano, Italy).

p65 nuclear translocation
-------------------------

Lungs were excised and homogenized using a trans Turrax homogenizer. Cytoplasmatic and nuclear extracts were obtained using Nuclear Extraction Kit (Active Motif, La Hulpe, Belgium), and determination of p65 was carried out using TransAM NFkB p65 transcription factor assay kit (Active Motif), according to the manufacturer instructions.

Data analysis
-------------

As tests for normality were positive, statistical analysis was performed on raw data using one-way analysis of variance (ANOVA) followed by Dunnett\'s *t* post-hoc test for comparison with control groups. Experimental values were expressed as the mean and standard error of the mean (SEM) of *n* observations. (\**P* \< 0.05, \*\**P* \< 0.01).

Results
=======

As previously reported, LPS intratracheal instillation 1 week after DNA delivery of the luciferase reporter construct caused activation of NF-*κ*B that could be easily monitored by BLI, showing a very marked increase when compared to control animals (Fig. [1](#fig01){ref-type="fig"}A). Ex-vivo imaging of isolated lungs confirmed that the bioluminescence observed in vivo was associated to the activation of NF-*κ*B in the lungs (Fig. [1](#fig01){ref-type="fig"}B). *Luc* expression driven by NF-*κ*B activation was detectable by BLI as early as 2 h after LPS challenge, peaked at 4 h after treatment, with a 10-fold induction over baseline. This signal was still significantly enhanced 7 h after LPS, but returned to baseline levels 24 h after LPS challenge (Fig. [1](#fig01){ref-type="fig"}C). Double staining immunofluorescence analysis performed to identify which cell type(s) is(are) targeted by the injected plasmid DNA showed LPS-induced expression of luciferase in both epithelial (Fig. [2](#fig02){ref-type="fig"}A--D) or endothelial (Fig. [2](#fig02){ref-type="fig"}E--H) cells. While regular staining was observed for CK18 and CD31 (Fig. [2](#fig02){ref-type="fig"}I and K, and [Fig. S1](#SD1){ref-type="supplementary-material"}A and C), no signal for luciferase was observed in LPS-challenged wild type animals (Fig. [2](#fig02){ref-type="fig"}J) or in saline-challenged NF-*κ*B-luc animals ([Fig. S1](#SD1){ref-type="supplementary-material"}B and D).

![(A) In vivo imaging of NF-*κ*B activation 4 h after LPS challenge. LPS (12.5 *μ*g/mouse) was administered intratracheally. Representative mice are shown for saline and LPS groups. (B) Ex vivo imaging of NF-*κ*B activation in lungs excised 4 h after LPS treatment. Representative lungs are shown for saline and LPS groups. (C) Time-course of luciferase induction in mice challenged with intratracheal LPS. Values are shown as mean ± SEM, *n* = 12 at each time point *P* \< 0.05, \*\**P* \< 0.01 versus saline group (Dunnett\'s *t* test).](prp20002-e00058-f1){#fig01}

![Double immunofluorescence staining of mice lungs. Duoplex immunofluorescence staining of luciferase/CK18 (epithelial cell marker) or luciferase/CD31(endothelial cell marker) were performed on paraformaldehyde-fixed lung sections, as described in Materials and Methods. Double staining showed that in LPS-challenged NF-kB-luc mice both epithelial cells (A) and endothelial cells (E) were expressing luciferase (B and F), and displayed yellow immunofluorescence when the two images were merged (C and G, respectively); larger magnifications of the merged images are reported in (D and H). Immunofluorescence staining of CK18 (I), luciferase (J) and CD31 (K) in LPS-challenged wild type mice, confirmed the absence of signal for luciferase. Original magnification: (A--C, E--G, and J) 210X; (D, H, I, and K) 600X.](prp20002-e00058-f2){#fig02}

Bortezomib (Velcade), a known proteasome inhibitor that interferes with the degradation of IkB and therefore the activation of NF-*κ*B, dose dependently inhibited luciferase expression 4 h after LPS administration (Fig. [3](#fig03){ref-type="fig"}A and B), lending support to the quantitative correlation between NF-*κ*B activation and bioluminescence determination in the transient transgenic mice. In agreement with the fact that the expression of adhesion molecules leading to white blood cells (WBC) extravasation and infiltration are results of NF-*κ*B activation (Read et al. [@b37]; Kalogeris et al. [@b22]; Dagia and Goetz [@b14]), increased numbers of WBC and neutrophils were also recovered by BAL 24 h after LPS challenge (Fig. [4](#fig04){ref-type="fig"}A and B) and this increase was also significantly inhibited by bortezomib treatment. A strong correlation was observed between bioluminescence observed 4 h after LPS administration and the number of WBC and neutrophils recovered by BAL 24 h after LPS challenge (Fig. [4](#fig04){ref-type="fig"}C), further supporting the ability of this transient transgenic mouse model to provide an accurate, in vivo determination of NF-*κ*B activation in the lung.

![(A--D) In vivo imaging of NF-*κ*B activation 4 h after LPS treatment: effects of pretreatment with bortezomib. Transient NF-*κ*B-luc transgenic mice were pretreated with saline or bortezomib (BZM, 0.5--1 mg/kg) i.v. 1 h before LPS intratracheal instillation. Representative mice are shown for saline (A), LPS (B), LPS+BZM 0.5 mg/kg (C) and LPS+BZM 1 mg/kg (D and E). Quantification of NF-*κ*B activation by BLI, 4 h after LPS intratracheal instillation. Values are shown as mean ± SEM, *n* = 8 for each group, and% inhibition versus LPS group is reported. \*\**P* \< 0.01 versus LPS group (Dunnett\'s *t* test)](prp20002-e00058-f3){#fig03}

![(A and B) LPS-induced neutrophil and white blood cells (WBC) recruitment in the airways: effects of bortezomib. Transient NF-*κ*B-luc transgenic mice were pretreated with saline or bortezomib (BZM, 0.5--1 mg/kg, i.v.) 1 h before LPS, and sacrificed 24 h after LPS administration by tracheal instillation. Values are shown as mean ± SEM, *n* = 8 for each group, and% inhibition versus LPS group is reported. \*\**P* \< 0.01 versus LPS group (Dunnett\'s test, C). Correlation between NF-*κ*B activation as measured by BLI, 4 h after LPS instillation, and the concentration of WBC in BAL lavage fluids, obtained 24 h after LPS instillation, in saline, LPS, LPS+BZM 0.5 mg/kg and LPS+BZM 1 mg/kg groups.](prp20002-e00058-f4){#fig04}

Pre-treatment of transient transgenic mice with azithromycin per os, dose-dependently inhibited bioluminescence induced by LPS tracheal instillation (9.5 ± 1.74 fold, 6.9 ± 1.82 and 4.16 ± 0.78 fold of induction over baseline at 4 h in LPS-control, azithromycin 100 mg/Kg p.o., and azithromycin 600 mg/Kg p.o., respectively) (Fig. [5](#fig05){ref-type="fig"}A and B). As observed with bortezomib, the inhibition of BLI was followed by a significant inhibition of WBC and neutrophil infiltration at 24 h confirming the anti-inflammatory activity of this compound (Fig. [6](#fig06){ref-type="fig"}A and B).

![(A and B) In vivo imaging of NF-*κ*B activation 4 h after LPS treatment: effect of azithromycin. Transient NF-*κ*B-luc transgenic mice were pretreated with saline or azithromycin (100--600 mg/Kg, *per os)* 4 h before LPS intratracheal instillation. Representative mice are shown for saline (A), LPS (B), LPS+AZI 100 mg/kg (C) and LPS+AZI 600 mg/kg (D).](prp20002-e00058-f5){#fig05}

![(A and B) LPS-induced WBC (A) and neutrophil (B) recruitment in the airways: effect of azithromycin. Transient NF-*κ*B-luc transgenic mice were pretreated with saline or Azithromycin (AZI, 100--600 mg/kg, *per os)* 4 h prior to LPS, and sacrificed 24 h after LPS administration by tracheal instillation. (C) Quantitation of NF-*κ*B activation by BLI, 4 h after LPS intratracheal instillation: effect of azithromycin. Values are shown as mean ± SEM, *n* = 8 for each group and% inhibition versus LPS group is reported. *P* \< 0.05, \*\**P* \< 0.01 versus LPS group (Dunnett\'s t test).](prp20002-e00058-f6){#fig06}

The inhibitory activity of azithromycin on NF-*κ*B activation, also resulted in a statistically significant inhibition in the BAL concentrations of several pro-inflammatory cytokines, such as TNF-*α*, granulocyte colony-stimulating factor (G-CSF) and monocyte chemoattractant protein-1 (MCP-1) (Fig. [7](#fig07){ref-type="fig"}A--F), while other cytokines upregulated by LPS were not affected ([Fig. S2](#SD2){ref-type="supplementary-material"}A--E). A complete list of cytokines analyzed is reported in [Table 1S](#SD3){ref-type="supplementary-material"}.

![(A--F) LPS-induced cytokines in bronchoalveolar lavage fluid (BALF): effect of azithromycin. Transient NF-*κ*B-luc transgenic mice were pretreated with saline or azithromycin (AZI, 100--600 mg/kg, *per os)* 4 h prior to LPS and sacrificed 24 h after tracheal instillation of LPS. A: TNF-*α*. B: eotaxin. C: G.CSF. D: IL-6. E: IL-9. F: MCP-1. Values are shown as mean ± SEM, *n* = 6 for each group and% inhibition versus LPS group is reported. *P* \< 0.05, \*\**P* \< 0.01 versus LPS group (Dunnett\'s t test)](prp20002-e00058-f7){#fig07}

Time-course of p65 nuclear translocation paralleled *luc* signal induction, with maximal accumulation occurring at 4 h, while by 24 h p65 was again localized primarily in cytoplasm (data not shown); azithromycin treatment inhibited by 52% (*P* \< 0.05) the nuclear translocation of activated NF-*κ*B observed in lung homogenates 4 h after LPS tracheal instillation.

Discussion
==========

The results obtained provided, for the first time, in vivo evidence that azithromycin treatment results in pulmonary anti-inflammatory activity associated with the inhibition of NF-*κ*B activation in the lung, as followed by bioluminescence monitoring in mice transiently transfected with luciferase gene under the control of an NF-*κ*B responsive element (Ansaldi et al. [@b4]).

While a limited number of evidence obtained in vitro using different cell types, including airways cells, pointed to the inhibition of NF-*κ*B as part of the mechanism of the anti-inflammatory activity of azithromycin (Aghai et al. [@b1]; Cigana et al. [@b12]; Matsumura et al. [@b29]; Vrancic et al. [@b42]), the only evidence available in vivo was obtained in a model of ocular inflammation, where it was shown that azithromycin treatment decreased the amount of NF-*κ*B protein detected by western blot in conjunctival homogenates, a measurement that does not actually evaluate changes in NF-*κ*B activation. On the other side, studying the activity of azithromycin in a model of LPS-induced pulmonary neutrophilia Boznar and co. could not show any inhibitory effect on NF-*κ*B activation in alveolar macrophages (Bosnar et al. [@b9]). The ability, offered by the animal model used in this study, to evaluate and monitor NF-*κ*B activation in vivo at the whole organ level, clearly showed that a significant activation of NF-*κ*B is indeed taking place in the lung upon intratracheal LPS challenge, and that azithromycin anti-inflammatory activity significantly inhibited NF-*κ*B activation-dependent bioluminescence. Luciferase co-expression with epithelial and endothelial cell-specific markers, as assessed by duoplex immunofluorescence, suggests that these cells may therefore represent potential targets of the activity of azithromycin. It must be noted that although cytokeratins are considered a typical marker of epithelial differentiation, they can also be expressed in certain vascular smooth muscle cells (Bar et al. [@b5]).

Although no infiltrating inflammatory cells showed up significantly expressing luciferase, this does not rule out the activation of NF-*κ*B in neutrophils, as their rapid turnover likely prevents them from being detected at the time-points used for LPS challenge after transient transfection.

NF-*κ*B activation upon LPS challenge resulted in a rather striking correlation between bioluminescence induced by NF-*κ*B activation and inflammatory biomarkers such as WBC and neutrophils airways infiltration, as shown by the parallelism between changes in these parameters induced by LPS alone or in the presence of increasing doses of a potent proteasome inhibitor (bortezomib) known to inhibit NF-*κ*B activation, by blocking the degradation of I*κ*B, the inhibitory unit of the NF-*κ*B complex, carried out by the 26S proteasome.

Dysregulation of NF-*κ*B activation has been involved in lung diseases such as asthma, chronic bronchitis, and COPD (Donovan et al. [@b16]; Teramoto and Kume [@b40]), but its specific contribution to disease progression is currently unknown (Lawrence et al. [@b26]). BLI provides a noninvasive approach to monitor gene expression in vivo and represent an important tool to evaluate the potential contribution of NF-*κ*B to the evolution of acute inflammatory reactions.

BLI is a powerful technique based on the detection of visible light produced during luciferase-mediated oxidation of a molecular substrate in the presence of the enzyme resulting from its expression in vivo as a molecular reporter. Bioluminescence arising from luciferase can be imaged as deep as several centimeters within tissues, allowing at least organ-level resolution. Being simple to execute and minimally invasive, BLI enables monitoring and serial quantification of biological processes without sacrificing the experimental animal. This powerful technique can therefore reduce the number of animals required for experimentation because multiple measurements can be made in the same animal over time, also minimizing the effects of biological variation.

In this study, we confirm the activity of azithromycin against pulmonary inflammation induced by LPS (Ianaro et al. [@b20]), showing a reduction in WBC and neutrophil airways infiltration and a significant decrease in the concentrations of proinflammatory cytokines in BAL. It must be noted that in this study azithromycin has been used prophylactically to prevent an acute inflammatory response mainly because we have been trying to establish a link between its anti-inflammatory activity and NF-*κ*B activation in vivo. Indeed, taking advantage of BLI on transiently transfected animals, we provide unequivocal evidence that this activity is associated with a significant inhibition of NF-*κ*B activation in vivo. Double immunofluorescence staining with antibodies targeting luciferase protein and specific cell type antigens, showed that in transient NF-*κ*B-luc transgenic mice intratracheal challenge with LPS induces luciferase expression both in epithelial and endothelial cells, suggesting a key role for these cell types in the inflammatory response to bacterial infection. Although no infiltrating inflammatory cells resulted in expressing luciferase, this does not rule out the activation of NF-*κ*B in these cells, but it rather reflects their rapid turnover.

This innovative analytical approach to the in vivo monitoring of pulmonary inflammation through the analysis of bioluminescence in transiently transfected mice, can certainly be used to test different macrolide antibiotics for their effects on NF-*κ*B activation, or, taking advantage of different vectors, to monitor different models of pathology (fibrosis, asthma etc.).

As previously reported, azithromycin was also able to significantly reduce the concentrations of G-CSF within the airways, and this activity may result in a decrease in epithelial cells-dependent neutrophil survival within the airways (Yamasawa et al. [@b45]), and contribute to the reported effects, among others, on COPD exacerbations (Albert et al. [@b2]; Yamaya et al. [@b47]).

Not much is known on the molecular mechanism of the inhibition of NF-*κ*B by azithomycin, but the possibility that the anti-inflammatory activity of macrolide antibiotics such as azythromycin or erythromycin may relate uniquely to their antibiotic activity has been ruled out by the identification of an erythromycin analog devoid of the antibiotic activity but retaining the anti-inflammatory action (Desaki et al. [@b15]). Conversely, it has been shown that azithromycin inhibits the binding of activator protein-1, nuclear factor of activated T cells, and interferon consensus sequence binding protein to the DNA-binding site in the IL-12p40 promoter (Yamauchi et al. [@b46]), and down regulation of TLR-4 receptor by azithromycin has also been reported (Iwamoto et al. [@b21]), and these could represent important mechanisms contributing to the anti-inflammatory effects of azithromycin.

In consideration of the striking correlation of NF-*κ*B activation as assessed by BLI, and downstream airway inflammatory responses, monitoring of BLI in this relatively simple model of transient transgenic mouse may represent a suitable approach for in vivo assessment of NF-*κ*B-associated inflammatory responses, and possess significant potential for the elucidation of molecular mechanisms in the pathobiology of lung diseases.

In conclusion, taking advantage of a transient transgenic mice expressing luciferase under the control of NF-*κ*B-responsive elements, we provide evidence that azithromycin inhibits NF-*κ*B activation in vivo, further supporting the important contribution of this mechanism of action to its anti-inflammatory activity.
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###### 

**Figure S1.** Double immunofluorescence staining of mice lungs. Duoplex immunofluorescence staining of luciferase/CK18 (epithelial cell marker) or luciferase/CD31(endothelial cell marker) were performed on paraformaldehyde-fixed lung sections, as described in Materials and Methods**.** Double staining of lung obtained from saline-challenged NF- *κ*B-luc mice showed normal staining of epithelial cells (A) and endothelial cells (C) for CK18 and CD31, respectively. On the contrary, no staining for luciferase was observed (B and D). Original magnification: 210×.

###### 

**Figure S2.** (A--E). LPS-induced cytokines in bronchoalveolar lavage fluid (BALF): effect of azithromycin. Transient NF-*κ*B-luc transgenic mice were pretreated with saline or azithromycin (AZI, 100--600 mg/kg, *per os)* 4 h prior to LPS and sacrificed 24 h after tracheal instillation of LPS. A: IL1-*α*. B: IL1-b. C: IL-12. D: IL-12(p70). E: KC. Values are shown as mean ± SEM, *n* = 6 for each group.

###### 

**Table S1.** Cytokines analyred in BAL of LPS-challenged mice. Cytokines modulated by LPS showed a statistically significant increase in BAL concentrations obtained after LPS challenge.
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